CN103443276B - 用于愈合或治疗伤口的分子靶标 - Google Patents

用于愈合或治疗伤口的分子靶标 Download PDF

Info

Publication number
CN103443276B
CN103443276B CN201280010963.9A CN201280010963A CN103443276B CN 103443276 B CN103443276 B CN 103443276B CN 201280010963 A CN201280010963 A CN 201280010963A CN 103443276 B CN103443276 B CN 103443276B
Authority
CN
China
Prior art keywords
ptprk
wounds
treating
wound
purposes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280010963.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN103443276A (zh
Inventor
姜文国
基斯·哈丁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University College Cardiff Consultants Ltd
Original Assignee
University College Cardiff Consultants Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University College Cardiff Consultants Ltd filed Critical University College Cardiff Consultants Ltd
Publication of CN103443276A publication Critical patent/CN103443276A/zh
Application granted granted Critical
Publication of CN103443276B publication Critical patent/CN103443276B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/29—Antimony or bismuth compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Enzymes And Modification Thereof (AREA)
CN201280010963.9A 2011-03-08 2012-02-17 用于愈合或治疗伤口的分子靶标 Active CN103443276B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1103898.1 2011-03-08
GBGB1103898.1A GB201103898D0 (en) 2011-03-08 2011-03-08 Molecular targets for healing or treating wounds
PCT/GB2012/050362 WO2012120269A1 (en) 2011-03-08 2012-02-17 Molecular targets for healing or treating wounds

Publications (2)

Publication Number Publication Date
CN103443276A CN103443276A (zh) 2013-12-11
CN103443276B true CN103443276B (zh) 2016-09-28

Family

ID=43923365

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280010963.9A Active CN103443276B (zh) 2011-03-08 2012-02-17 用于愈合或治疗伤口的分子靶标

Country Status (9)

Country Link
US (2) US20140213629A1 (enExample)
EP (1) EP2683823B1 (enExample)
JP (1) JP5986116B2 (enExample)
CN (1) CN103443276B (enExample)
AU (1) AU2012226593B2 (enExample)
CA (1) CA2829010A1 (enExample)
GB (2) GB201103898D0 (enExample)
IN (1) IN2013MN01547A (enExample)
WO (1) WO2012120269A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014183062A1 (en) 2013-05-10 2014-11-13 La Jolla Institute For Allergy And Immunology Autoimmune disease treatments
WO2015019125A1 (en) * 2013-08-05 2015-02-12 Societe De Developpement Et De Recherche Industrielle Molecular targets for the treatment of wounds, in particular chronic wounds
WO2020176790A1 (en) * 2019-02-27 2020-09-03 Fred Hutchinson Cancer Research Center Hydrogel compositions and methods for treatment of malignancies

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1362883A (zh) * 2000-02-21 2002-08-07 株式会社大熊制药 包含表皮生长因子作为活性成分的稳定组合物
WO2004005312A1 (en) * 2002-07-03 2004-01-15 Isis Pharmaceuticals Inc. Antisense modulation of ptprk expression
CN1649619A (zh) * 2002-03-12 2005-08-03 生物键有限公司 采用表皮生长因子治疗皮肤伤口的方法和组合物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204000B1 (en) 1995-04-28 2001-03-20 The United States Of America As Represented By The Department Of Health And Human Services Diagnostic methods and gene therapy using reagents derived from the human metastasis suppressor gene KAI1
US20050215629A1 (en) 2001-09-07 2005-09-29 Taolin Yi PTPase inhibitors and methods of using the same
WO2003070158A2 (en) * 2001-09-07 2003-08-28 The Cleveland Clinic Foundation Therapeutic compositions and methods useful in modulating protein tyrosine phosphatases
US7844214B2 (en) 2002-03-02 2010-11-30 Nokia Corporation System and method for broadband digital broadcasting
CA2506619A1 (en) 2002-11-18 2004-08-19 Thomas W. Hodge Cell lines and host nucleic acid sequences related to infectious disease
WO2004050894A2 (en) 2002-11-27 2004-06-17 Artesian Therapeutics, Inc. Heart failure gene determination and therapeutic screening
GB2396106B (en) * 2002-12-12 2006-11-15 Johnson & Johnson Medical Ltd Wound dressings comprising enzyme inhibitors
AU2004274973A1 (en) 2003-09-19 2005-03-31 Aviaradx, Inc. Predicting breast cancer treatment outcome
US20050170445A1 (en) 2004-01-07 2005-08-04 Duke University Methods of establishing profiles for use in evaluating wound healing and biocompatibility of implant materials and microarrays useful therefor
WO2006108225A1 (en) 2005-04-11 2006-10-19 Garvan Institute Of Medical Research Method of screening for compounds that modulate cell proliferation
WO2007130423A2 (en) 2006-05-01 2007-11-15 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Biological markers of chronic wound tissue and methods of using for criteria in surgical debridement
WO2008005276A2 (en) * 2006-06-30 2008-01-10 Directcontact Llc Growth factor delivery system containing antimicrobial agents
EP2242852A4 (en) 2007-12-07 2011-02-09 Univ Oregon Health & Science PROCEDURE FOR DETERMINING WHETHER AN INDIVIDUAL REQUIRES A BCR ABL INHIBITOR
US20110305703A1 (en) 2008-12-08 2011-12-15 Vegenics Pty Limited Isolated vegf-c and vegf-d peptides and uses thereof
US20120190042A1 (en) 2009-01-22 2012-07-26 Reuben Gobezie Protein biomarkers and therapeutic targets for osteoarthritis
CN101671729B (zh) 2009-09-07 2012-09-05 张力建 用于肺癌治疗方案选择和/或预后评估的基因群、基因芯片和检测试剂盒
GB0916124D0 (en) 2009-09-15 2009-10-28 Univ Cardiff Method and kit for the classification and prognosis of wounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1362883A (zh) * 2000-02-21 2002-08-07 株式会社大熊制药 包含表皮生长因子作为活性成分的稳定组合物
CN1649619A (zh) * 2002-03-12 2005-08-03 生物键有限公司 采用表皮生长因子治疗皮肤伤口的方法和组合物
WO2004005312A1 (en) * 2002-07-03 2004-01-15 Isis Pharmaceuticals Inc. Antisense modulation of ptprk expression

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Inside the human cancer tyrosine phosphatome;Sofi G. Julien et al.;《Nature Reviews》;20110131;第11卷;摘要，第45页右栏第5段 *
Randomized,Double-Blind Study of Stibogluconate Plus Human Granulocyte Macrophage Colony-Stimulating Factor versus Stibogluconate Alone in the Treatment of Cutaneous Leishmaniasis;Roque Almeida et al.;《The Journal of Infectious Disease》;19991008;第180卷(第5期);1735-1737 *
Receptor-type Protein-tyrosine Phosphatase-k Regulates Epodermal Growth Factor Receptor Function;Yiru Xu et al.;《Journal of Biological Chemistry》;20051031;第280卷(第52期);42694-42700 *
Treatment of Cutaneous Leishmaniasis with Allopurinol and Stibogluconate;S.Martinez et al.;《Clinical Infectious Diseases》;19970201;第24卷(第2期);165-169 *
Treatment of cutaneous leishmaniasis with intralesional sodium stibogluconate;M Solomon et al.;《Journal of the European Academy of Dermatology and Venereoligy》;20091001;第23卷(第10期);1189-1192 *

Also Published As

Publication number Publication date
IN2013MN01547A (enExample) 2015-06-12
HK1192904A1 (zh) 2014-09-05
CA2829010A1 (en) 2012-09-13
AU2012226593B2 (en) 2016-06-02
EP2683823A1 (en) 2014-01-15
EP2683823B1 (en) 2016-07-20
US9782381B2 (en) 2017-10-10
JP2014511392A (ja) 2014-05-15
JP5986116B2 (ja) 2016-09-06
US20140213629A1 (en) 2014-07-31
GB2502017A (en) 2013-11-13
US20160331716A1 (en) 2016-11-17
GB201314859D0 (en) 2013-10-02
AU2012226593A1 (en) 2013-09-12
GB201103898D0 (en) 2011-04-20
CN103443276A (zh) 2013-12-11
WO2012120269A1 (en) 2012-09-13

Similar Documents

Publication Publication Date Title
Ding et al. TGF-β1 protects against mesangial cell apoptosis via induction of autophagy
Binet et al. Neuronal ER stress impedes myeloid-cell-induced vascular regeneration through IRE1α degradation of netrin-1
Poulaki et al. Insulin-like growth factor-I plays a pathogenetic role in diabetic retinopathy
Kaufman et al. Advances in glaucoma treatment and management: outflow drugs
US20200276166A1 (en) Methods of treating neurological disorders
Wang et al. Upregulation of CCR3 by age-related stresses promotes choroidal endothelial cell migration via VEGF-dependent and-independent signaling
CN110538327A (zh) Gpr31抑制剂在制备治疗脂肪代谢异常及相关疾病的药物中的应用
Zhou et al. Tetrahedral framework nucleic acids inhibit pathological neovascularization and vaso‐obliteration in ischaemic retinopathy via PI3K/AKT/mTOR signalling pathway
JP2018138596A (ja) 眼の状態を処置および／または防止するためのｓｉＲＮＡならびに方法および組成物におけるそれらの使用
Zhu et al. Crosstalk between RPE cells and choroidal endothelial cells via the ANXA1/FPR2/SHP2/NLRP3 inflammasome/pyroptosis axis promotes choroidal neovascularization
Chen et al. SYVN1 promotes STAT3 protein ubiquitination and exerts antiangiogenesis effects in retinopathy of prematurity development
CN103443276B (zh) 用于愈合或治疗伤口的分子靶标
Xia et al. Inhibition of retinal neovascularization by siRNA targeting VEGF165
Lei et al. Lentiviral delivery of small hairpin RNA targeting connective tissue growth factor blocks profibrotic signaling in tenon's capsule fibroblasts
Zheng et al. Orai1 expression pattern in tooth and craniofacial ectodermal tissues and potential functions during ameloblast differentiation
ES2750125T3 (es) ARNip y su uso en métodos y composiciones para el tratamiento y/o la prevención de afecciones oculares
WO2015132303A1 (en) Sirnas and their use in methods and compositions for the treatment and/or prevention of eye conditions
WO2012117334A1 (en) Mglur5 positive allosteric modulators for use in the treatment phelan-mcdermid syndrome
Yu et al. METTL14-mediated m6A methylation regulates pathological retinal neovascularization by targeting autophagy
KR20210088446A (ko) 세포 투과성 핵산 복합체를 유효성분으로 함유하는 황반변성의 예방 또는 치료용 조성물
EP2542677B1 (en) Molecular targets for healing or treating wounds
AU2021205373B2 (en) Composition for preventing or treating macular degeneration, containing cell permeable nucleic acid complex as active ingredient
CN120204428A (zh) 一种ITGB1-siRNA脂质纳米粒及其在抗新生血管治疗中的应用
Long et al. Chemerin-CMKLR1 differentially mediated OGD/R-induced mitochondrial dysfunction, oxidative stress, and autophagy in microglia and neurons
Zhu et al. CX3CL1 attenuates neurological deficit and neuroinflammation through CX3CR1/p38 MAPK/ERK1/2 signaling pathway in traumatic brain injury

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant